235 related articles for article (PubMed ID: 31280000)
1. Inverse Relationship of BMI to TSH and Risk of Papillary Thyroid Cancer in Surgical Patients.
Handelsman RS; Alvarez AL; Picado O; Farrá JC; Lew JI
J Surg Res; 2019 Dec; 244():96-101. PubMed ID: 31280000
[TBL] [Abstract][Full Text] [Related]
2. The incidence of papillary thyroid carcinoma and outcomes in operative patients according to their body mass indices.
Trésallet C; Seman M; Tissier F; Buffet C; Lupinacci RM; Vuarnesson H; Leenhardt L; Menegaux F
Surgery; 2014 Nov; 156(5):1145-52. PubMed ID: 24878452
[TBL] [Abstract][Full Text] [Related]
3. Body mass index in the evaluation of thyroid cancer risk.
Mijović T; How J; Pakdaman M; Rochon L; Gologan O; Hier MP; Black MJ; Young J; Tamilia M; Payne RJ
Thyroid; 2009 May; 19(5):467-72. PubMed ID: 19415996
[TBL] [Abstract][Full Text] [Related]
4. Influence of body mass index on the clinicopathological features of 13,995 papillary thyroid tumors.
Li CL; Dionigi G; Zhao YS; Liang N; Sun H
J Endocrinol Invest; 2020 Sep; 43(9):1283-1299. PubMed ID: 32166701
[TBL] [Abstract][Full Text] [Related]
5. Thyroid-Stimulating Hormone, Thyroid Hormones, and Risk of Papillary Thyroid Cancer: A Nested Case-Control Study.
Huang H; Rusiecki J; Zhao N; Chen Y; Ma S; Yu H; Ward MH; Udelsman R; Zhang Y
Cancer Epidemiol Biomarkers Prev; 2017 Aug; 26(8):1209-1218. PubMed ID: 28377419
[No Abstract] [Full Text] [Related]
6. Levothyroxine Cessation After Thyroid Lobectomy for Papillary Thyroid Cancer Can Be Achieved at the Same Rate as that for Benign Tumors Regardless of the Duration of Thyroid-stimulating Hormone Suppression.
Na YM; Cho JS; Park MH
Anticancer Res; 2021 Nov; 41(11):5713-5721. PubMed ID: 34732444
[TBL] [Abstract][Full Text] [Related]
7. Association between preoperative thyrotrophin and clinicopathological and aggressive features of papillary thyroid cancer.
Tam AA; Ozdemir D; Aydın C; Bestepe N; Ulusoy S; Sungu N; Ersoy R; Cakir B
Endocrine; 2018 Mar; 59(3):565-572. PubMed ID: 29374347
[TBL] [Abstract][Full Text] [Related]
8. Obesity and High Risk Pathological Features of Papillary Thyroid Carcinoma: A Retrospective Analysis of a University Hospital in Pakistan.
Zaman SU; Awan MS; Sulaiman MA
Gulf J Oncolog; 2018 May; 1(27):6-10. PubMed ID: 30145545
[TBL] [Abstract][Full Text] [Related]
9. Factors influencing TSH suppression efficacy in postoperative papillary thyroid carcinoma patients: a retrospective cohort study.
Zhang Q; Zhong ZZ; Wu T; He YQ
BMC Surg; 2024 May; 24(1):133. PubMed ID: 38702652
[TBL] [Abstract][Full Text] [Related]
10. Preoperative thyroid-stimulating hormone associated risk of differentiated thyroid cancer in patients with thyroid nodules.
M AE
Cell Mol Biol (Noisy-le-grand); 2021 Nov; 67(3):85-91. PubMed ID: 34933729
[TBL] [Abstract][Full Text] [Related]
11. Association of obesity with the clinicopathological features of thyroid cancer in a large, operative population: A retrospective case-control study.
Zhao S; Jia X; Fan X; Zhao L; Pang P; Wang Y; Luo Y; Wang F; Yang G; Wang X; Gu W; Zang L; Pei Y; Du J; Ba J; Dou J; Mu Y; Lyu Z
Medicine (Baltimore); 2019 Dec; 98(50):e18213. PubMed ID: 31852078
[TBL] [Abstract][Full Text] [Related]
12. Obesity and the risk of papillary thyroid cancer: a pooled analysis of three case-control studies.
Xu L; Port M; Landi S; Gemignani F; Cipollini M; Elisei R; Goudeva L; Müller JA; Nerlich K; Pellegrini G; Reiners C; Romei C; Schwab R; Abend M; Sturgis EM
Thyroid; 2014 Jun; 24(6):966-74. PubMed ID: 24555500
[TBL] [Abstract][Full Text] [Related]
13. Fasting serum glucose, thyroid-stimulating hormone, and thyroid hormones and risk of papillary thyroid cancer: A case-control study.
Hu MJ; Zhang C; Liang L; Wang SY; Zheng XC; Zhang Q; Jiang CX; Zhong Q; Huang F
Head Neck; 2019 Jul; 41(7):2277-2284. PubMed ID: 30759328
[TBL] [Abstract][Full Text] [Related]
14. Potential impact of obesity on the aggressiveness of low- to intermediate-risk papillary thyroid carcinoma: results from a MASTER cohort study.
Kim M; Kang YE; Park YJ; Koo BS; Ku EJ; Choi JY; Lee EK; Kim BH
Endocrine; 2023 Oct; 82(1):134-142. PubMed ID: 37516686
[TBL] [Abstract][Full Text] [Related]
15. Association of Body Mass Index With Clinicopathological Features of Papillary Thyroid Carcinoma: A Retrospective Study.
Dong Z; Liu W; Su F; Cheng R
Endocr Pract; 2023 Feb; 29(2):83-88. PubMed ID: 36481471
[TBL] [Abstract][Full Text] [Related]
16. Effects of endocrine therapy on the prognosis of elderly patients after surgery for papillary thyroid carcinoma.
Xia Q; Dong S; Bian PD; Wang J; Li CJ
Eur Arch Otorhinolaryngol; 2016 Apr; 273(4):1037-43. PubMed ID: 25744048
[TBL] [Abstract][Full Text] [Related]
17. RET/PTC Rearrangements Are Associated with Elevated Postoperative TSH Levels and Multifocal Lesions in Papillary Thyroid Cancer without Concomitant Thyroid Benign Disease.
Su X; He C; Ma J; Tang T; Zhang X; Ye Z; Long Y; Shao Q; Shao J; Yang A
PLoS One; 2016; 11(11):e0165596. PubMed ID: 27802347
[TBL] [Abstract][Full Text] [Related]
18. Is thyroid hormone supplementation avoidable for patients with low-risk papillary thyroid cancer after thyroid lobectomy? A two-center observational study.
Xiao L; Wu J; Jiang L; Xu Y; Liu B
Clin Endocrinol (Oxf); 2022 Mar; 96(3):413-418. PubMed ID: 34398464
[TBL] [Abstract][Full Text] [Related]
19. Biochemical Markers Reflecting Thyroid Function in Athyreotic Patients on Levothyroxine Monotherapy.
Ito M; Miyauchi A; Hisakado M; Yoshioka W; Ide A; Kudo T; Nishihara E; Kihara M; Ito Y; Kobayashi K; Miya A; Fukata S; Nishikawa M; Nakamura H; Amino N
Thyroid; 2017 Apr; 27(4):484-490. PubMed ID: 28056660
[TBL] [Abstract][Full Text] [Related]
20. Postoperative Thyroid-Stimulating Hormone Levels Did Not Affect Recurrence after Thyroid Lobectomy in Patients with Papillary Thyroid Cancer.
Lee MC; Kim MJ; Choi HS; Cho SW; Lee GH; Park YJ; Park DJ
Endocrinol Metab (Seoul); 2019 Jun; 34(2):150-157. PubMed ID: 31099202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
